| LRRK2 — Leucine-Rich Repeat Kinase 2 | |
|---|---|
| Gene | LRRK2 |
| UniProt ID | [Q5S007](https://www.uniprot.org/uniprot/Q5S007) |
| PDB Structures | 6VP6, 7LHW, 7LI4, 4D0G |
| Molecular Weight | 286 kDa (2527 aa) |
| Subcellular Localization | Cytoplasm, membranes, mitochondria |
| Protein Family | ROCO family (Kinase + GTPase) |
| Domain Architecture | ARM, ANK, LRR, ROC, COR, Kinase |
LRRK2 (Leucine-Rich Repeat Kinase 2), also known as Dardarin (from the Basque "dardara" meaning "trembling"), is a large multi-domain protein encoded by the LRRK2 gene. It belongs to the ROCO protein family and is one of the most significant genetic risk factors for Parkinson's disease[@muller2023].
LRRK2 has a complex multi-domain structure:
| Domain | Function | Disease Relevance |
|---|---|---|
| LRR | Protein-protein interactions | Mutations may affect binding |
| ROC | GTPase activity | G2019S increases kinase activity |
| COR | Kinase regulation | Autophosphorylation |
| Kinase | Phosphotransferase | Major drug target |
| WD40 | Scaffold function | C-terminal interactions |
Neuronal Development
Cellular Signaling
Protein Homeostasis
Mitochondrial Function
### Pathogenic Mechanisms
LRRK2 mutations cause PD through multiple mechanisms:
1. **Kinase Hyperactivity**
- G2019S (most common) increases kinase activity 2-3 fold
- Leads to enhanced substrate phosphorylation
- Causes toxic gain-of-function
2. **GTPase Dysregulation**
- Impaired GTP hydrolysis
- Constitutive activation
- Altered protein interactions
3. **Cellular Dysfunction**
- Impaired autophagy-lysosome pathway
- Mitochondrial dysfunction
- Synaptic defects
4. **Neuroinflammation**
- Microglial activation
- Increased cytokine production
- Enhanced neuroinflammation
### Cellular Consequences
#### Autophagy Dysregulation
LRRK2 hyperactivation impairs autophagy:
- **mTORC1 hyperactivation**: Prevents autophagy initiation
- **Lysosomal dysfunction**: Reduced clearance
- **Protein aggregates**: Accumulation
#### Mitochondrial Dysfunction
LRRK2 affects mitochondria:
- **PINK1/Parkin pathway**: Altered mitophagy
- **Mitochondrial dynamics**: fission/fusion imbalance
- **Energy production**: Reduced ATP
#### Synaptic Failure
Synaptic dysfunction in LRRK2 models:
- **Vesicle cycling**: Impaired release
- **Spine morphology**: Reduced spines
- **Neurotransmission**: Altered signaling
See also: LRRK2 Pathway in Parkinson's Disease.
### Common Pathogenic Mutations
| Mutation | Location | Effect | Frequency |
|----------|----------|--------|-----------|
| **G2019S** | Kinase | Increased activity | 5% familial, 1% sporadic |
| **R1441C/G/H** | ROC | Impaired GTPase | ~3% familial |
| **N1437H** | ROC | Reduced activity | Rare |
| **G2385R** | WD40 | Risk factor | 10% Asian populations |
| **R1628P** | WD40 | Risk factor | Higher in Asian |
## Clinical Features of LRRK2-PD
### Motor Symptoms
LRRK2-associated PD shows typical motor features:
- Resting tremor
- Bradykinesia
- Rigidity
- Postural instability
Typically slower progression than sporadic PD.
### Non-Motor Symptoms
- Sleep disorders: REM sleep behavior disorder
- Olfactory dysfunction: Anosmia
- Autonomic dysfunction: Constipation
## Therapeutic Targeting
LRRK2 is a **major drug target** for PD:
### Kinase Inhibitors
Several LRRK2 inhibitors in development:
- **DNL151/DNL312** (Denali) — Phase 1/2
- **BIIB122** (Biogen) — Phase 2
- **MLi-2** — Preclinical tool compound
See also: [LRRK2 Inhibitors](/therapeutics/lrrk2-inhibitors).
### Challenges
1. **Brain Penetration:** Achieving sufficient CNS exposure
2. **Peripheral Effects:** Safety concerns with chronic inhibition
3. **Wild-type Inhibition:** Side effects from inhibiting normal LRRK2
## Structural Biology
### Cryo-EM Structures
Recent advances have revealed the full-length LRRK2 structure[@alessi2023]:
**Full-length architecture**:
- L-shaped dimeric structure
- Coordinated Rock-Kinase module
- C-terminal WD40 scaffold
**Active conformations**:
- Back-to-back dimer formation
- ROC domain dimerization
- Kinase activation loop flexibility
### GTPase Cycle
The ROC domain functions as a GTPase:
**GTP binding**:
- Promotes LRRK2 dimerization
- Activates kinase domain
- Enables autophosphorylation
**GTP hydrolysis**:
- ROC domain hydrolyzes GTP to GDP
- Regulated by COR domain
- Mutations affect hydrolysis rate
**GDP release**:
- Slow release rate
- Rate-limiting step
- Drug targeting opportunity
## Expression Pattern
| Tissue | Expression Level |
|--------|-----------------|
| Brain (highest in substantia nigra) | High |
| Kidney | High |
| Lung | Moderate |
| Heart | Low-Moderate |
| Liver | Low |
## Interacting Proteins
LRRK2 interacts with numerous proteins:
- **α-Synuclein** — Pathological interaction
- **Parkin** — Mitophagy regulation
- **PINK1** — Mitochondrial quality control
- **14-3-3 proteins** — Cytosolic anchoring
- **VPS35** — Retromer component
- **Rab proteins** — Primary substrates
- **MAPK components** — Signaling pathways
- **mTOR** — Autophagy regulation
### LRRK2-Rab Interaction Network
```mermaid
flowchart LR
classDef blue fill:#e1f5fe,stroke:#01579b,stroke-width:2px
classDef orange fill:#fff3e0,stroke:#e65100,stroke-width:2px
classDef green fill:#c8e6c9,stroke:#1b5e20,stroke-width:2px
classDef red fill:#ffcdd2,stroke:#b71c1c,stroke-width:2px
A["LRRK2"]:::blue -->|"phosphorylates"| B["Rab10"]:::orange
A -->|"phosphorylates"| C["Rab8A"]:::orange
A -->|"phosphorylates"| D["Rab12"]:::orange
A -->|"phosphorylates"| E["Rab35"]:::orange
B -->|"regulates"| F["Membrane Traffic"]:::green
C -->|"regulates"| G["Exocytosis"]:::green
D -->|"regulates"| H["Autophagy"]:::green
E -->|"regulates"| I["Endocytosis"]:::green
F -.->|defect| J["PD Pathogenesis"]:::red
G -.-> J
H -.-> J
I -.-> J
click A "/genes/lrrk2" "LRRK2 Gene"
click A "/proteins/lrrk2-protein" "LRRK2 Protein"
click H "/mechanisms/autophagy-lysosomal-pathway-parkinsons" "Autophagy Pathway"
click J "/diseases/parkinsons-disease" "Parkinson's Disease"
LRRK2 is highly expressed in microglia:
Activation markers:
Cytokine production:
The LRRK2 hyperactivation → microglial activation → chronic inflammation → neuronal loss cascade.
LRRK2 plays important roles in neurons[@greggio2021]:
Synaptic function:
Axonal function:
Neuronal survival:
LRRK2 is highly expressed in glia:
Microglia:
Astrocytes:
The International LRRK2 Consortium has identified genetic modifiers[@gclass2020]:
Risk modifiers:
Protective modifiers:
LRRK2 penetrance is modified by:
LRRK2-targeted therapies are in various stages of development [@muller2023]:
LRRK2 mutation carriers show specific biomarkers [@fang2022]:
Key LRRK2 models include [@greggio2021]:
The G2019S mutation is the most common pathogenic variant [@kluss2022]:
Research priorities for LRRK2 [@alessi2023]:
Understanding LRRK2 phosphorylation targets is crucial for drug development:
Rab proteins (Rab3A, Rab8A, Rab10, Rab12, Rab35)
MAPK signaling components
Autophagy proteins
LRRK2 biomarker development focuses on: